Trade

with

WuXi PharmaTech (Cayman) Inc
(NYSE: WX)
AdChoices
36.75
+0.36
+0.99%
After Hours :
36.89
+0.14
+0.37%

Open

36.40

Previous Close

36.39

Volume (Avg)

460.80k (358.54k)

Day's Range

36.36-37.10

52Wk Range

28.57-40.72

Market Cap.

2.53B

Dividend Rate ( Yield )

-

Beta

1.17

Shares Outstanding

69.50M

P/E Ratio (EPS)

24.04 (1.51)

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Diagnostics & Research
Highlights
Analyst Recommendation: Underperform
    • Revenue

    • 578.08M

    • Net Income

    • 114.57M

    • Market Cap.

    • 2.53B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • 17.98

    • PEG (Price/Earnings Growth) Ratio

    • 1.60

    • Beta

    • 1.17

    • Forward P/E

    • 19.34

    • Price/Sales

    • 4.33

    • Price/Book Value

    • 3.70

    • Price/Cash flow

    • 14.64

      • EBITDA

      • 184.72M

      • Return on Capital %

      • 12.49

      • Return on Equity %

      • 16.57

      • Return on Assets %

      • 12.49

      • Book Value/Share

      • 9.84

      • Shares Outstanding

      • 69.50M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Underperform
        • 1 Year Price Target

        • 25.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • 1.88

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 14.80

          • 21.91

          • Net Income

            YTD/YTD (last year)

          • 32.30

          • -5.55

          • Net Income

            Q/Q (last year)

          • -1.00

          • 0.44

          • Sales (Revenue)

            5-Year Annual Average

          • 17.93

          • 47.82

          • Net Income

            5-Year Annual Average

          • -

          • 4.98

          • Dividends

            5-Year Annual Average

          • -

          • 5.31

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 37.07

            • 42.70

            • Pre-Tax Margin

            • 21.96

            • 11.63

            • Net Profit Margin

            • 17.98

            • 9.55

            • Average Gross Margin

              5-Year Annual Average

            • 38.00

            • 43.76

            • Average Pre-Tax Margin

              5-Year Annual Average

            • 24.10

            • 11.34

            • Average Net Profit Margin

              5-Year Annual Average

            • 20.80

            • 52.13B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.02

              • 0.62

              • Current Ratio

              • 2.47

              • 1.23

              • Quick Ratio

              • 2.15

              • 0.76

              • Interest Coverage

              • -

              • 5.98

              • Leverage Ratio

              • 1.38

              • 2.16

              • Book Value/Share

              • 9.84

              • 14.94

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • 24.10

                • 32.79

                • P/E Ratio 5-Year High

                • 26.94

                • 325.07

                • P/E Ratio 5-Year Low

                • 7.05

                • 154.73

                • Price/Sales Ratio

                • 4.33

                • 2.30

                • Price/Book Value

                • 3.70

                • 2.98

                • Price/Cash Flow Ratio

                • 14.64

                • 18.76

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • 16.57

                    (19.80)

                  • 9.34

                    (9.80)

                  • Return on Assets %

                    (5-Year Average)

                  • 12.49

                    (14.80)

                  • 4.63

                    (5.44)

                  • Return on Capital %

                    (5-Year Average)

                  • 14.48

                    (17.00)

                  • 5.73

                    (6.77)

                  • Income/Employee

                  • 14.83k

                  • 17.17k

                  • Inventory Turnover

                  • 9.35

                  • 5.07

                  • Asset Turnover

                  • 0.69

                  • 0.48

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  105.24M
                  Operating Margin
                  18.21
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  14.64
                  Ownership

                  Institutional Ownership

                  95.48%

                  Top 10 Institutions

                  46.68%

                  Mutual Fund Ownership

                  52.30%

                  Float

                  -

                  5% / Insider Ownership

                  -

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • FPIL First State China Growth

                  •  

                    2,620,992

                  • 0.00

                  • 3.77

                  • Columbia Acorn International Fund

                  •  

                    2,500,000

                  • 0.00

                  • 3.60

                  • SK USD Schroder ISF Asian Total Ret IRL

                  •  

                    1,769,520

                  • 0.00

                  • 2.59

                  • Schroder ISF Asian Opportunities

                  •  

                    1,609,110

                  • 0.00

                  • 2.35

                  • ZI Fidelity China Focus

                  •  

                    1,293,534

                  • 0.00

                  • 1.86

                  • Oppenheimer International Small Co Fund

                  •  

                    1,171,934

                  • 0.00

                  • 1.69

                  • Invesco Greater China Equity Fund

                  •  

                    1,022,078

                  • 0.00

                  • 1.48

                  • OMGB Investec GSF Asian Equity

                  •  

                    928,586

                  • 2.79

                  • 1.34

                  • HSBC QDII-Fidelity Funds - Em Markets Fd

                  •  

                    903,835

                  • 48.23

                  • 1.30

                  • CI Black Creek Global Leaders

                  •  

                    887,770

                  • 0.00

                  • 1.28

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Wellington Management Company, LLP

                  •  

                    5,382,584

                  • +81.44%

                  • 7.74

                  • Schroder Investment Mgmt (Singapore) Ltd

                  •  

                    4,680,639

                  • +8.91%

                  • 6.73

                  • Fidelity International Ltd

                  •  

                    4,312,186

                  • +14.12%

                  • 6.20

                  • Columbia Wanger Asset Management LLC

                  •  

                    3,361,141

                  • +0.79%

                  • 4.84

                  • Fidelity Management and Research Company

                  •  

                    2,755,095

                  • -21.30%

                  • 3.96

                  • Colonial First State Glbl Asset Mgmt

                  •  

                    2,726,223

                  • -4.42%

                  • 3.92

                  • Friends Provident International Limited

                  •  

                    2,620,992

                  • 0.00%

                  • 3.77

                  • Mirae Asset Global Investments Co Ltd

                  •  

                    2,370,406

                  • +0.60%

                  • 3.41

                  • Investec Asset Management Ltd.

                  •  

                    2,208,986

                  • +112.51%

                  • 3.18

                  • Blair William & Co

                  •  

                    2,033,448

                  • -27.74%

                  • 2.93

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Diagnostics & Research

                  Type

                  -

                  Style

                  -

                  WuXi PharmaTech (Cayman), Inc. was incorporated on March 16, 2007 and commenced operations and began offering pharmaceutical and biotechnology R&D outsourcing services in 2001. The Company is a pharmaceutical, biotechnology and medic...moreal device R&D services company, with operations in China and the United States. It provides a portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process to its customers, which includes premier pharmaceutical, biotechnology and medical device companies. Its services are designed to assist its customers in shortening the cycle and lowering the cost of pharmaceutical and medical device R&D by providing cost-effective and efficient outsourcing solutions. Its primary China-based facilities include 1,127,000 square feet of facilities...more in the China (Shanghai) Pilot Free Trade Zone used for synthetic chemistry, biology, medicinal chemistry, DMPK, formulation, analytical development, manufacturing process chemistry, research manufacturing, bioanalytical services, genomics, and biologics drug discovery and development; an R&D center in Tianjin engaged in synthetic chemistry and medicinal chemistry; a facility in Wuhan providing services in synthetic chemistry and medicinal chemistry; a small-scale cGMP clinical manufacturing facility and a large-scale cGMP commercial manufacturing plant in the Jinshan district of Shanghai; a large-scale non-GMP manufacturing plant in Changzhou; a preclinical toxicology facility in Suzhou; a laboratory for manufacturing research reagents in Suzhou; and a biologics manufacturing facility in Wuxi. It also offers services in biologics and medical device testing in three FDA-registered facilities in the United States. The Company has two segments: Laboratory services and Manufacturing services. Laboratory services are provided for pharmaceutical, biotechnology and medical device companies. China-based laboratory services for pharmaceutical and biotechnology companies include services for small molecules, such as synthetic chemistry, biology, medicinal chemistry, DMPK/ADME, formulation, analytical chemistry, toxicology, clinical development, bioanalytical services, genomics, research reagent production, and clinical services, as well as services for discovery and development of biologics. U.S.-based laboratory services include testing services for biologics, medical devices, and combination products. Manufacturing services include the development of manufacturing processes and the production of advanced intermediates and active pharmaceutical ingredients, or APIs, for use by pharmaceutical companies in preclinical and clinical trials of small-molecule products and in commercial products, as well as the production of biologics. The Company offers testing and development services to ensure that a medical device is manufactured, packaged and sterilized in accordance with GMP guidelines. Its in vivo and in vitro toxicology testing includes biocompatibility or safety testing; orthopedic, cardiovascular and custom implant studies; histology and pathology services; analytical chemistry and chemical / physical testing; raw material verification; lot release testing; sterilization validation; microbial identifications; process change validation; inactivation / clearance validation; package integrity testing; cleaning/sterilization validation for reusable devices; and controlled environment monitoring. Its competitors include ShangPharma Corporation, Pharmaron Inc., Covance Inc., Charles River Laboratories International, Inc. BioReliance, a division of Sigma-Aldrich Corporation, and North American Science Associates Inc. and Toxikon, among others.lessless

                  Key People

                  Ge Li,PhD

                  CEO/Chairman of the Board/Director/Founder

                  Xiaozhong Liu

                  Director/Executive VP/Founder

                  Zhaohui Zhang

                  Director/Founder/Other Corporate Officer/Senior VP, Divisional

                  Edward Hu

                  CFO/COO

                  Mr. Alexander Fowkes

                  Vice President, Divisional

                  • WuXi PharmaTech (Cayman) Inc

                  • 288 Fute Zhong Road

                  • Shanghai, 200131

                  • CYM.Map

                  • Phone: +86 2150461111

                  • Fax: +86 2150461000

                  • wuxiapptec.com

                  Incorporated

                  2007

                  Employees

                  7,445

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: